Nanotechnology Now

• About Us
  
  • Advertising
  • Our Mission
  • Our Team
  • Comments
  • Friends
  • Contact
• Nanotechnology
• News
  
  • Current News
  • Press Releases
  • Submit Press
  • Press kit
  • Interviews
• Columns
• Products
  
  • Our Products
  • Books
  • Featured Books
• Directories
  
  • Companies/Academic
  • Events
  • Glossary
  • Best Of
• Career Center
• Nano-Social Network
• Nano Consulting
• My Account

Home > News > Positive ABRAXANE(TM) Phase III Trial in Metastatic Breast Cancer

September 24th, 2003

Positive ABRAXANE(TM) Phase III Trial in Metastatic Breast Cancer

Abstract:
American Pharmaceutical Partners, Inc.and American BioScience, Inc. (ABI) announced today that the
primary efficacy objective has been exceeded in the randomized, controlled Phase III clinical trial in 460 patients with metastatic breast cancer of ABRAXANE(TM) versus the Cremophor(R) solvent-based TAXOL. Initial
analysis of the data indicates that this solvent-free nanoparticle paclitaxel, ABRAXANE, resulted in higher anti-tumor activity and was not more toxic than TAXOL.

Source:
APP

Bookmark:

Related News Press

Nanomedicine

3-D printing could lead to tiny medical implants, electronics, robots, more June 18th, 2013

Pioneering breakthrough of chemical nanoengineering to design drugs controlled by light June 18th, 2013

Study Shows How the Nanog Protein Promotes Growth of Head and Neck Cancer June 18th, 2013

Production of Polyaniline Biosensors Modified with Conductive Polymer Composites June 18th, 2013